anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our study is planned as a prospective observational study. Patients undergoing therapeutic hypothermia in our intensive care unit after cardiac arrest will be enrolled. Each patient's cerebral oxygenation will be monitored with near-infrared spectroscopy (NIRS) in every 6 hours during our 24 hour lasting hypothermia period. Afterwards, patients will be monitorised in every 6 hours during the first day of hypothermia and than the mean values of daily cerebral oxygen values will be noted in the third, fourth and fifth days of nomothermia. Regional oxygen saturation (rSO2) will be noted from left and right probes. Full Outline of Unresponsiveness (FOUR) Score, Glasgow Coma Score (GCS) and cerebral performance category scale (CPC) will be noted at the beginning of therapeutic hypothermia and each day during normothermia, day 21 and the day of discharge from ICU.
Safety and effectiveness of venlafaxine hydrochloride extended-release capsules in pediatric patients have not been established. 

Two placebo-controlled trials in 766 pediatric patients with MDD and two placebo-controlled trials in 793 pediatric patients with GAD have been conducted with venlafaxine hydrochloride extended-release capsules, and the data were not sufficient to support use in pediatric patients.

In the studies conducted in pediatric patients ages 6 to 17 years, the occurrence of blood pressure and cholesterol increases was considered to be clinically relevant in pediatric patients and was similar to that observed in adult patients [see Warnings and Precautions (5.3), Adverse Reactions (6.1)]. The following adverse reactions were also observed in pediatric patients: abdominal pain, agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.

Although no studies have been designed to primarily assess venlafaxine hydrochloride extended-release capsules impact on the growth, development, and maturation of children and adolescents, the studies that have been done suggest that venlafaxine hydrochloride extended-release capsules may adversely affect weight and height [see Warnings and Precautions (5.10, 5.11)]. Decreased appetite and weight loss were observed in placebo-controlled studies of pediatric patients 6 to 17 years. 

In pediatric clinical studies, the adverse reaction, suicidal ideation, was observed. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning, Warnings and Precautions (5.1)].
In addition to standard of care, opaganib will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. When required this may be made into a suspension form and may be administered by nasogastric tube.
Medical records were collected in each group for birth history data, including gestational age (GA), birth weight (BW), and postmenstrual age (PMA) at time of intravitreal injection. The zone and stage of ROP were also recorded. All patients were evaluated for refractive errors and cycloplegic refraction was performed using a handheld auto keratorefractometer (Righton Retinomax K-plus2), and confirmed by retinoscopy examination. Refractive errors were calculated as spherical equivalent and astigmatism in cylinder. The average corneal radius of curvature was measured by handheld auto kerato-refractometer (Righton Retinomax K-plus2). The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)
The invention features a catheter (1) for delivering drugs to tissue at a desired location of the wall of a body lumen (2). The catheter (1) has a catheter shaft (3) and an expandable portion (4) mounted on the catheter shaft (3). The expandable portion (4) is expandable to a controlled pressure to fill the cross section of the body lumen (2) and press against the wall of the body lumen (2). At least a portion of the exterior surface of the expandable portion (4) is defined by a coating (6) of a tenaciously adhered swellable hydrogel polymer. Incorporated in the hydrogel polymer is an aqueous solution (8) of a preselected drug to be delivered to the tissue or plaque. The hydrogel polymer (6) and drug (8) are selected to allow rapid release of a desired dosage of the drug from the hydrogel polymer coating (6) during compression of the hydrogel polymer coating (6) against the wall of the lumen (2) when the expandable portion (4) is expanded.
Evidence suggests that an advanced stage of disease with high plasma viremia is associated with increased transmission of HIV-1 to the fetus. Slowing the progression of disease, reducing the titer of virus in plasma, and increasing the titer of epitope-specific antibody are potentially attainable goals through active immunization of the mother during pregnancy.

Pregnant women are randomized to receive an initial injection of MN rgp120 vaccine or alum placebo between week 16 and week 24 of gestation, followed by monthly booster injections concluding at the end of pregnancy, for a total of five injections. Patients may have optional booster immunizations (vaccine or placebo) at 3, 6, 9, and 12 months after delivery. Mothers and infants are followed through 18 months after delivery. Per 06/94 addendum, patients will be contacted once or twice per year for at least 5 years to check on health status of patient and child. PER 12/21/94 ADDENDUM, post-partum immunizations are discontinued.
PURPOSE:To obtain the titled preparation giving a flexible coating film when applied to the skin and dried, and having excellent stability with time and high infiltration property and adhesivity to the skin, by dissolving an antimycotic compound, a film-forming resin and a plasticizier in a solvent under specific condition. CONSTITUTION:3-40pts.wt. of preferably an antimycotic compound, especially clotrimazole, 100pts.wt. of a film-forming resin (e.g. ethylcellulose, polyvinyl butyral, etc.) and 33-200pts.wt. of a plasticizier to impart flexibility to the coating film (e.g. isopropyl myristate, diethyl sebacate, etc.) are dissolved in 400-1,800pts.wt. of a solvent (e.g. ethanol). The pH of the preparation shaken together with 10 times volume of water is adjusted to >=7. The adjustment of the pH improves the stability of the principal drug with time, releasability of the drug from the coating film, and the infiltration property to the skin. It has higher therapeutic effect than conventional antimycotic drug for external application having acidic pH.
The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency, and in addition some patients may experience symptoms of withdrawal, e.g., joint and/or muscular pain, lassitude, and depression. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a severe exacerbation of their symptoms.

The concomitant use of intranasal corticosteroids with other inhaled corticosteroids could increase the risk of signs or symptoms of hypercorticism and/or suppression of the HPA axis.

A drug interaction study in healthy subjects has shown that ritonavir (a highly potent cytochrome P450 3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations (see CLINICAL PHARMACOLOGY: Drug Interactions and PRECAUTIONS: Drug Interactions). During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing syndrome and adrenal suppression. Therefore, coadministration of fluticasone propionate and ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.

Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered.

Avoid spraying in eyes.
In the control group, patients were orally administered at the starting dose of 80mg qd for 21 days after enrollment. On the 21st day of the 4th cycle, if the patient has no tumor progression and no intolerable toxicity, the patient will continue to receive Linperlisib 80mg qd after the investigator determines that the drug therapy can be continued, and the safety and tumor efficacy evaluation will be conducted regularly until the disease progresses, toxicity becomes intolerable, or the investigator determines that the treatment is not suitable for further treatment. The maximum duration of treatment is two years.
This group consists of 25 individuals diagnosed with chronic migraine. They will undergo cervical joint repositioning error assessment in different head positions.
A health food contg. eicosapentaenoic acid (EPA) is prepd. by i) extracting ginseng with ethanol and concentrating to obtain the ginseng extract, ii) mixing 5-30 wt parts ginseng extract with 10-75 wt.% Pur EPA extracted from a sardine, 0.5-10 wt parts natural tocopherol, 0.5-10 wt parts ascorbic acid and 10-70 wt parts shortening oil, iii) emulsifying the obtd. mixt. at 40 deg.C or less by homogenizing, and iv) filling gelatin capsule with the obtd. emulsifyed mixt.. The obtd. health food is useful for the prevention of adult disease.
The objective of this work was to compare the effects of two balance training programs, one Nintendo Wii Fit-based and the other traditionally-based without the use of a gaming system, on the balance, functionality and cognition of patients with Parkinson´s disease. It was a prospective, single blinded, randomized clinical trial performed at Brazil Parkinson Association and Center of Research of the courses of Speech Therapy, Physical Therapy and Occupational Therapy of São Paulo University. 32 patients with Parkinson´s disease on stages 1 and 2,5 of Hoehn e Yahr participated of this work. Patients were randomized in control and experimental group, 16 each one. Both groups performed 14 training sessions, twice a week, for seven weeks. Each session was composed of a 30 minute-global-exercise series including stretching, muscle strengthen and axial mobility exercises. After this, both groups performed more 30 minutes of balance training: the control group performed balance exercises without external cues, visual or auditory feedbacks or cognitive stimulations; the experimental group performed the balance training with 10 Wii Fit games which stimulated motor and cognitive functions. The main outcome measures were: (1) Unified Parkinson´s Disease Rating Scale (UPDRS); (2) Berg Balance Scale (BBS); (3) Unipedal Stance Test (UST) and (4) Montreal Cognitive Assessment (MoCA). The statistical analysis was done by repeated measures ANOVA in order to assess the possible differences among the analyzed variables. Both groups showed improvement in the section II of UPDRS, BBS, UST and MoCA. Patients with Parkinson´s disease showed balance and cognitive improvement with positive repercussion on daily living activities after 14 sessions of balance training without additional advantages to the virtual training.
The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
Participants randomized to receive Morphine and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid .szlig.(A.szlig.) peptide linked to a helper T cell epitope (Th) having multiple class II MHX binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the A.szlig. peptide and generate antibodies, which are highly cross-reactive to the soluble A.szlig.1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble A.szlig.1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the "soluble A.szlig.-derived toxins"; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.
The invention provides an anti-aging composition and application thereof, wherein the composition comprises the following components in percentage by mass: RAR agonists: ergothioneine: pseudo-ginsenoside f11=1: 0.1-10:0.1-5: 0.5-15, and the content of ergothioneine is 1000-2000 ppm. The invention enhances the anti-aging efficacy of the bakuchiol by adding the RAR agonist serving as an active ingredient into the bakuchiol. By adding ergothioneine, the ergothioneine can increase the anti-aging effect of the composition. Meanwhile, ergothioneine can increase the antioxidation rate of bakuchiol. The invention also comprises the pseudo-ginsenoside F11, and the pseudo-ginsenoside F11 and the rest components have synergistic effect. The composition provided by the invention has obvious anti-aging effect, mild ingredients and comfortable use feeling, can be widely applied to cosmetic skin care products such as cosmetics and the like, and has important significance in research and development of anti-aging products.
The co-occurrence of multiple chronic metabolic diseases is highly prevalent, posing a huge health threat. Clarifying the metabolic associations between them, as well as identifying metabolites which allow discrimination between diseases, will provide new biological insights into their co-occurrence. Herein, we utilized targeted serum metabolomics and lipidomics covering over 700 metabolites to characterize metabolic alterations and associations related to seven chronic metabolic diseases (obesity, hypertension, hyperuricemia, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, fatty liver) from 1626 participants. We identified 454 metabolites were shared among at least two chronic metabolic diseases, accounting for 73.3% of all 619 significant metabolite-disease associations. We found amino acids, lactic acid, 2-hydroxybutyric acid, triacylglycerols (TGs), and diacylglycerols (DGs) showed connectivity across multiple chronic metabolic diseases. Many carnitines were specifically associated with hyperuricemia. The hypercholesterolemia group showed obvious lipid metabolism disorder. Using logistic regression models, we further identified distinguished metabolites of seven chronic metabolic diseases, which exhibited satisfactory area under curve (AUC) values ranging from 0.848 to 1 in discovery and validation sets. Overall, quantitative metabolome and lipidome data sets revealed widespread and interconnected metabolic disorders among seven chronic metabolic diseases. The distinguished metabolites are useful for diagnosing chronic metabolic diseases and provide a reference value for further clinical intervention and management based on metabolomics strategy.
The invention relates to an application of myristica fragrans volatile oil in preparation of a medicament for treating a depressive disorder. A medication problem of the depressive disorder can be effectively solved. According to the technical scheme for solving the problem, an extraction method of the myristica fragrans volatile oil comprises the following steps: crushing myristica fragrans into powder by a 2# sieve; adding distilled water which is 7-9 times of weight of the myristica fragrans to the powder; soaking for 5-7 hours; and heating and extracting for 9 hours, so as to obtain the myristica fragrans volatile oil. The myristica fragrans volatile oil disclosed by the invention is applied to preparation of the medicament for treating the depressive disorder. Thus, the problem of prevention and treatment of the depressive disorder is solved, and a new use of the myristica fragrans volatile oil for preventing and treating the depressive disorder is opened up. Therefore, the myristica fragrans volatile oil is an innovation in the traditional Chinese medicine.
Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of escitalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for escitalopram.

In managing overdosage, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.
Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
Participants in Japan receive MK-3475A (pembrolizumab Conc1 \[dose 1\] + MK-5180) SC on Day 1 of Cycle 1, with background SOC chemotherapy, and then receive 400 mg pembrolizumab IV on Day 1 of Cycles 2 to 18, with background SOC chemotherapy. A cycle is 42 days.
For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
PURPOSE: An attention deficit hyperactivity disorder model animal, a method for evaluating the prevention and alleviation of attention deficit diseases, and a composition therefore are provided to be used in the attention deficit therapeutic agent screening. CONSTITUTION: An attention deficit hyperactivity disorder model animal is constituted as follows. A cobalt wire is transplanted in the right frontal lobe of the brain of a mouse. After the cobalt wire is transplanted, the brain of the mouse is sutured. A mouse showing the attention deficit disease is selected. An attention deficit therapeutic agent screening method is as follows. An object compound or a composition is administered an attention deficiency model mouse. The brain wave of the deficiency model mouse is measured and is compared with a control group. An object compound or a composition with reduced spike number is selected.
Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
The present invention is directed to a speculum assembly for single-use in colon lavage therapy. The speculum assembly comprises a tubular body to which a tubing-set is attached. The tubular body has a leading end, a middle portion, and a trailing end. The leading end has a tapering body transitioning into a tip, a scallop opening adjacent to the tip, and at least one annular rib about the tubular body, positioned between the scallop opening and the middle portion. The middle portion has a flange. The flange is in communication with a portion of an irrigation tube. The trailing end of the tubular body comprises a handle that selectively retains a portion of the irrigation tube and attaches to a portion of a waste hose, elements of the tubing set.
<P>PROBLEM TO BE SOLVED: To provide a means suppressing relapse and metastasis and further increasing the effect in radiotherapy of radiation resistant cancer except hypoxic state, by irradiating radiation in the presence of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.  <P>SOLUTION: In radiotherapy of cancer having radiation resistance, a radiation sensitizer of chemical formula 1 is used to sensitize and treat. The compound of chemical formula 1 of 10-400 mg is administered based on 1 kg body weight of animal or human and radiation is irradiated. The radiation resistant cancer is preferably lung adenocarcinoma. Fractionated irradiation therapy comprising administering 10-400 mg compound of formula 1 per 1 kg body weight to the animal or the human and then repeating 5-40 times irradiation of 1-10 Gy is preferable.  <P>COPYRIGHT: (C)2008,JPO&INPIT